## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

No clear thesis: MRS_10 at 4.1%, does not meet entry criteria. Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($238.99)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Humana Inc. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251203T163000 | Bullish | Relevance: 99%
- Humana Inc. (HUM) stock experienced a significant rise of 6.18% on a strong trading day for the overall stock market. This increase to $256.92 broke a three-day losing streak for the company. The S&P 500 Index and the Dow Jones Industrial Average also saw gains, indicating a favorable market session.

**2. How Epic, Humana are automating insurance verification**
- Source: TechTarget | 20251203T142603 | Bullish | Relevance: 99%
- Humana and Epic have launched a digital insurance verification workflow that eliminates the need for physical insurance cards, streamlining patient registration and potentially reducing claim denials. This automation has already supported over 800,000 Humana Medicare Advantage members across 120 health systems, with early data showing a 50% reduction in registration time. The collaboration aims to improve provider-payer interoperability, with plans to expand to prior authorization modernization.

**3. Mark Cuban's Cost Plus Drugs, Humana exploring partnership to tackle employer drug costs**
- Source: Fierce Healthcare | 20251205T000827 | Bullish | Relevance: 98%
-  Mark Cuban's Cost Plus Drugs and Humana are in discussions about a potential partnership aimed at reducing prescription drug costs for employers. This collaboration would leverage Humana's CenterWell healthcare services business to offer a direct-to-employer model for prescription drugs, effectively bypassing traditional pharmacy benefit managers. Both companies emphasize the need for transparency and simplification in the drug supply chain to deliver better value to consumers and employers.

**4. Humana working with Mark Cuban on potential pharmacy partnership**
- Source: Modern Healthcare News | 20251204T145100 | Somewhat-Bullish | Relevance: 98%
- Humana is reportedly in discussions with Mark Cuban to develop direct-to-employer pharmacy programs. This partnership aims to streamline the drug supply chain by bypassing traditional intermediaries. The initiative could significantly impact how employers provide pharmaceutical benefits to their employees.

**5. Panagora Asset Management Inc. Purchases 117,580 Shares of Humana Inc. $HUM**
- Source: MarketBeat | 20251203T123215 | Somewhat-Bullish | Relevance: 97%
- Panagora Asset Management Inc. significantly increased its stake in Humana Inc. by purchasing 117,580 shares in Q2 2025, bringing its total holdings to 118,359 shares valued at approximately $28.94 million. This comes as Humana Inc. beat Q3 earnings estimates with $3.24 EPS on revenues of $32.65 billion, an 11.1% year-over-year increase. Analyst sentiment remains mixed, with a "Hold" consensus rating and a target price of $295.94.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Jefferies | $313 | $253 | +24% |
| 2025-11-25 | Barclays | $234 | $245 | -4% |
| 2025-11-10 | Truist Securiti | $285 | $300 | -5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Jefferies | up | Buy |
| 2025-11-25 | Barclays | main | Equal-Weight |
| 2025-11-10 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +3.1% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.0x). Analyst sentiment negative (2 target cuts vs 1 raises). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $30.1B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 20.4 |
| Current P/E | 15.1 |
| YoY Growth | -25.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from 1.0% to 4.1% (+3.1% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 86th percentile. MRS_5 at 2.4% confirms short-term momentum alignment. Outperforming sector by 6.4pp, stock-specific strength. Below SMA200 (1.00x), long-term trend not supportive. MACD histogram positive (3.92), confirming momentum. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 4.09% (CS: 87) | Strong |
| RSI_14 | 55.5 | Neutral |
| MACD Histogram | 3.92 | Bullish |
| vs SMA20 | 1.073x | Above |
| vs SMA50 | 0.982x | Below |
| vs SMA200 | 0.997x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $257.85
- **Stop Loss:** $238.99 (7.3% risk)
- **Target:** $276.71 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 26
- **Position Value:** $6,704.10
- **Portfolio %:** 6.70%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*